Arcutis Biotherapeutics, Inc. - ARQT STOCK NEWS

Arcutis presented new data on their investigational roflumilast cream 0.15% for treating mild to moderate atopic dermatitis (AD) in individuals aged six and above. The study showed that the cream provided sustained improvements in AD symptoms over 56 weeks, with 66.2% of participants achieving a 75% improvement in Eczema Area and Severity Index (EASI-75). Additionally, 56.6% achieved disease clearance with continued use, and those who switched to a proactive twice-weekly application maintained disease control for a median duration of 281 days. The cream was well-tolerated with no new safety issues reported. Adverse events were generally mild to moderate, with only 3% discontinuing due to adverse effects. These results highlight the potential of roflumilast cream as a long-term, steroid-free treatment option for AD.

Arcutis Biotherapeutics (Nasdaq: ARQT) announced the grant of 57,500 restricted stock units to six new employees. These units were approved by the Compensation Committee and are part of the Arcutis Biotherapeutics 2022 Inducement Plan, effective June 3, 2024. The grants are intended to attract new talent, as stipulated under Nasdaq Listing Rule 5635(c)(4). The units will vest over four years, with 25% vesting each year, contingent upon ongoing employment with the company.

Arcutis Biotherapeutics (Nasdaq: ARQT) will present five abstracts at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference from June 8-10, 2024, in Chicago, IL. The presentations include new long-term safety and efficacy data of roflumilast cream 0.15% for mild to moderate atopic dermatitis in patients aged 6 and above. Preclinical data on ARQ-234, a CD200 receptor agonist for atopic dermatitis, will also be showcased. Additional presentations will cover the consistent tolerability profile of topical roflumilast in psoriasis, seborrheic dermatitis, and atopic dermatitis. The company aims to advance the standard of care for chronic, immune-mediated skin diseases.

Arcutis Biotherapeutics (Nasdaq: ARQT) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference from June 10-13, 2024. The event will feature a fireside chat on June 12 at 1:20 pm ET, accessible via webcast on the company's website. The replay will remain available for 180 days post-conference. Arcutis specializes in innovations in immuno-dermatology, aiming to provide significant advancements in this field.

Arcutis Biotherapeutics reported a strong performance in Q1 2024, with net product revenues of $21.6M for its ZORYVE® franchise, showing a 675% year-over-year growth. ZORYVE cream and foam contributed $15M and $6.5M, respectively. The company expects further GTN improvements and is preparing for a key FDA decision on July 7, 2024, regarding roflumilast cream for treating atopic dermatitis. Arcutis raised $172.5M from a public offering and secured a strategic licensing agreement in Japan. The company also reported a net loss of $35.4M, an improvement from the $80.1M loss in Q1 2023.

Arcutis Biotherapeutics, Inc. announced the validation of ZORYVE foam for treating Seborrheic Dermatitis across diverse hair types. A panel of experts expressed confidence in prescribing the foam for various skin and hair types based on formulation data. The use of Crodafos CES in the formulation makes ZORYVE suitable for all affected body areas, highlighting its versatility and efficacy. The company received positive feedback from the expert panel, affirming the gentle and effective nature of the foam for patients with different hair and skin types.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) granted restricted stock units and options to 13 new employees as an inducement for joining the company. The awards were approved by the Compensation Committee of Arcutis' Board of Directors and are part of the 2022 Inducement Plan. The grants are subject to vesting conditions over four years, with stock options having a ten-year term and an exercise price of $8.84 per share.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) will report first quarter 2024 financial results on May 14, 2024, after the U.S. financial markets close. The company will also provide a business update and host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast and presentation material on the company's website.